Bayer Doubles Down on American Manufacturing as Pipeline and Balance Sheet Get a Rework
Published on 10/04/2026 at 12:20 | Editorial boerse-global.deBayer is betting that scale in the world's largest pharmaceutical market will eventually pay for itself. The Leverkusen-based group wants to double its US pharma revenue by the end of the decade, and CEO Bill Anderson is staking that ambition on building out domestic capacity rather than leaning on imports.
The centerpiece of that strategy landed Friday: a roughly $2.2 billion manufacturing complex in New Albany, Ohio, where Bayer intends to combine active ingredient output with finished-dose production under one roof. The site will span 200 acres. Construction alone is expected to generate about 1,500 building trades jobs, with some 600 permanent, highly skilled positions once the facility is running.
Patience will be required. The plant is not slated to come online until 2031, and finished-drug production is penciled in for 2034 at the earliest. That long runway sits at the heart of investor caution toward the stock, since years will pass before the new capacity contributes measurable margin — a stretch during which financial discipline has to hold.
A Decade of US Spending Behind the Pledge
The Ohio project is not a standalone gesture. Bayer has invested more than $7 billion in US pharmaceutical research, development and production over the past five years, according to the Deutsche Presse-Agentur. The company's US push is concentrated on cancer, heart disease and kidney conditions, the therapeutic areas where it sees the deepest growth potential.
Should investors sell immediately? Or is it worth buying Bayer?
Analysts frame the trade-off in familiar terms: expansion opens new revenue channels but ties up substantial capital, and whether the multibillion-dollar outlay rewards shareholders depends on execution and on how regulation evolves in the world's biggest pharma market.
Politics has attached itself to the announcement. Over the weekend, former US President Donald Trump publicly highlighted the investment and attributed it to his hardline tariff policy. Anderson, for his part, stressed the US role as a central production and innovation hub that will help Bayer supply innovative medicines worldwide.
Personnel and Pipeline Moves Run in Parallel
While the manufacturing story unfolds, Bayer has been reshuffling its prescription-drug business. On Thursday the group named Dr. Christoph Koenen as Chief Medical Officer of its pharma division, effective October 1. Koenen keeps his existing role leading clinical development and operations, consolidating medical oversight and trial leadership under one executive so that strategic development programs are steered from a single desk.
The research pipeline delivered a regulatory win as well. Subsidiary BlueRock Therapeutics said Wednesday that both the FDA and the EMA granted Orphan Drug designation to Lemiretprocel, also known as OpCT-001, a development candidate aimed at certain inherited retinal diseases. The status is designed to encourage therapies for rare conditions and gives developers procedural support through the remaining clinical testing.
Portfolio Trimming and a Fresh Refinancing
Recent weeks have also brought portfolio housekeeping. On September 21, Bayer agreed to sell rights to the cancer drug Stivarga to pharmaceutical company Grünenthal for up to EUR 375 million, with completion expected in late 2026 or early 2027. Two days later, on September 23, management placed EUR 2 billion in hybrid bonds across two separate tranches, lifting the total outstanding volume of these subordinated notes to EUR 6.55 billion.
Bayer at a turning point? This analysis reveals what investors need to know now.
The market has taken a dim view of the near term. Bayer shares closed Friday at EUR 45.02, a modest 0.6 percent decline on the day, and the stock has shed 10 percent over the past seven sessions. The pullback leaves the equity consolidating after a longer stretch of recovery.
Even so, the broader trend remains positive: Bayer is up 22 percent since the start of the year, a gain that suggests investors are still giving credit to the group's restructuring course — provided the Ohio buildout, the pipeline and the balance sheet all stay on script.
Ad
Bayer Stock: New Analysis - 4 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
